TVTX on Nasdaq
Travere Therapeutics, Inc.
American pharmaceutical preparations company, incorporated in California.
Price unavailable
Last updated Oct 18, 2026.
Overview
Compare with Nature's Sunshine Products, BridgeBio or Mirum Pharmaceuticals, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Filspari brought in 66% of the revenue Travere Therapeutics, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Filspari | $29.2M | $132.2M | $322.0M |
| Tiopronin Products | $98.3M | $94.5M | $88.5M |
| License | $17.7M | $6.5M | $80.3M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue2¢$10.3M
- Selling, general and admin69¢$337.2M
- Other costs29¢$142.2M
- Income tax0¢$988.0K
Out of $490.7M in revenue.3 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Kept or used elsewhere100¢$37.8M
Out of $37.8M of cash from operations.3
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $490.7M | $233.2M | $145.2M |
| Cost of goods sold | $10.3M | $7.7M | $11.4M |
| Research and development | $206.0M | $217.5M | $245.0M |
| Selling, general and administrative | $337.2M | $264.1M | $265.5M |
| In-process research and development | $0 | $65.2M | $0 |
| Restructuring | $0 | $2.4M | $11.4M |
| Total operating expenses | $553.6M | $557.0M | $533.4M |
| Operating loss | -$62.8M | -$323.8M | -$388.1M |
| Interest income | $12.7M | $17.8M | $21.8M |
| Interest expense | -$10.7M | -$11.2M | -$11.3M |
| Other income (expense), net | $11.6M | -$3.3M | $1.6M |
| Total other income, net | $13.6M | $3.3M | $12.0M |
| Loss from continuing operations before income tax provision | -$49.3M | -$320.5M | -$376.1M |
| Income tax provision on continuing operations | -$988.0K | -$120.0K | -$223.0K |
| Loss from continuing operations, net of tax | -$50.3M | -$320.6M | -$376.3M |
| Income (loss) from discontinued operations, net of tax | $24.7M | -$915.0K | $264.9M |
| Net loss from continuing operations, basic (in dollars per share) | -$1 | -$4 | -$5 |
| Net loss from continuing operations, diluted (in dollars per share) | -$1 | -$4 | -$5 |
| Net income (loss) from discontinued operations, basic (in dollars per share) | $0 | -$0 | $4 |
| Net income (loss) from discontinued operations, diluted (in dollars per share) | $0 | -$0 | $4 |
| Net loss per common share, basic (in dollars per share) | -$0.29 | -$4.08 | -$1.50 |
| Net loss per common share, diluted (in dollars per share) | -$0.29 | -$4.08 | -$1.50 |
| Weighted average common shares outstanding, basic (in shares) | 89.2M shares | 78.9M shares | 74.3M shares |
| Weighted average common shares outstanding, diluted (in shares) | 89.2M shares | 78.9M shares | 74.3M shares |
| Net loss | -$25.5M | -$321.5M | -$111.4M |
| Unrealized gain (loss) on defined benefit pension plan | $219.0K | $328.0K | -$374.0K |
| Foreign currency translation (loss) gain | -$945.0K | $1.4M | -$1.9M |
| Unrealized (loss) gain on marketable debt securities | -$383.0K | -$374.0K | $3.7M |
| Comprehensive loss | -$26.7M | -$320.2M | -$109.9M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $93.0M | $58.5M | ||
| Marketable debt securities, at fair value | $229.8M | $312.2M | ||
| Accounts receivable, net | $80.1M | $27.1M | ||
| Inventory | $5.9M | $6.2M | ||
| Prepaid expenses and other current assets | $28.8M | $12.7M | ||
| Total current assets | $437.6M | $416.7M | ||
| Long-term inventory | $30.3M | $35.7M | ||
| Property and equipment, net | $4.0M | $5.3M | ||
| Operating lease right-of-use assets | $10.6M | $14.3M | ||
| Intangible assets, net | $113.9M | $104.0M | ||
| Other assets | $8.9M | $18.2M | ||
| Total assets | $605.2M | $594.1M | ||
| Accounts payable | $24.8M | $23.5M | ||
| Accrued expenses | $126.0M | $86.0M | ||
| Convertible debt, current portion | $0 | $68.7M | ||
| Operating lease liabilities, current portion | $5.9M | $5.4M | ||
| Other current liabilities | $3.2M | $17.1M | ||
| Total current liabilities | $159.9M | $200.8M | ||
| Convertible debt, less current portion | $311.7M | $310.3M | ||
| Operating lease liabilities, less current portion | $11.1M | $17.2M | ||
| Other non-current liabilities | $7.6M | $6.8M | ||
| Total liabilities | $490.4M | $535.0M | ||
| Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock $0.0001 par value; 200,000,000 shares authorized; 90,922,868 and 87,452,835 issued and outstanding as of December 31, 2025 and 2024, respectively | $9.0K | $9.0K | ||
| Additional paid-in capital | $1.6B | $1.5B | ||
| Accumulated deficit | -$1.5B | -$1.4B | ||
| Accumulated other comprehensive loss | -$1.2M | -$80.0K | ||
| Total stockholders' equity | $114.8M | $59.1M | $200.8M | $42.9M |
| Total liabilities and stockholders' equity | $605.2M | $594.1M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 20.0M shares | 20.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, issued (in shares) | 90.9M shares | 87.5M shares | ||
| Common stock, outstanding (in shares) | 90.9M shares | 87.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $93.0M | $58.5M | ||
| Marketable debt securities, at fair value | $229.8M | $312.2M | ||
| Accounts receivable, net | $80.1M | $27.1M | ||
| Inventory | $5.9M | $6.2M | ||
| Prepaid expenses and other current assets | $28.8M | $12.7M | ||
| Total current assets | $437.6M | $416.7M | ||
| Long-term inventory | $30.3M | $35.7M | ||
| Property and equipment, net | $4.0M | $5.3M | ||
| Operating lease right-of-use assets | $10.6M | $14.3M | ||
| Intangible assets, net | $113.9M | $104.0M | ||
| Other assets | $8.9M | $18.2M | ||
| Total assets | $605.2M | $594.1M | ||
| Accounts payable | $24.8M | $23.5M | ||
| Accrued expenses | $126.0M | $86.0M | ||
| Convertible debt, current portion | $0 | $68.7M | ||
| Operating lease liabilities, current portion | $5.9M | $5.4M | ||
| Other current liabilities | $3.2M | $17.1M | ||
| Total current liabilities | $159.9M | $200.8M | ||
| Convertible debt, less current portion | $311.7M | $310.3M | ||
| Operating lease liabilities, less current portion | $11.1M | $17.2M | ||
| Other non-current liabilities | $7.6M | $6.8M | ||
| Total liabilities | $490.4M | $535.0M | ||
| Preferred stock $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding as of December 31, 2025 and 2024 | $0 | $0 | ||
| Common stock $0.0001 par value; 200,000,000 shares authorized; 90,922,868 and 87,452,835 issued and outstanding as of December 31, 2025 and 2024, respectively | $9.0K | $9.0K | ||
| Additional paid-in capital | $1.6B | $1.5B | ||
| Accumulated deficit | -$1.5B | -$1.4B | ||
| Accumulated other comprehensive loss | -$1.2M | -$80.0K | ||
| Total stockholders' equity | $114.8M | $59.1M | $200.8M | $42.9M |
| Total liabilities and stockholders' equity | $605.2M | $594.1M | ||
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, authorized (in shares) | 20.0M shares | 20.0M shares | ||
| Preferred stock, issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Common stock, issued (in shares) | 90.9M shares | 87.5M shares | ||
| Common stock, outstanding (in shares) | 90.9M shares | 87.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$25.5M | -$321.5M | -$111.4M |
| Net income (loss) from discontinued operations | $24.7M | -$915.0K | $264.9M |
| Net loss from continuing operations | -$50.3M | -$320.6M | -$376.3M |
| Depreciation and amortization | $60.7M | $43.6M | $38.5M |
| Share based compensation | $44.9M | $36.9M | $44.2M |
| In-process research and development | $0 | $65.2M | $0 |
| Loss on allowance for inventory | $684.0K | $2.8M | $3.0M |
| Amortization of debt discount and issuance costs | $1.6M | $1.7M | $1.7M |
| Amortization of discounts on investments | -$4.4M | -$4.5M | -$7.5M |
| Other | -$1.5M | $7.9M | -$3.6M |
| Accounts receivable | -$27.8M | -$6.0M | -$11.3M |
| Inventory | $5.0M | -$3.8M | -$39.4M |
| Income taxes | $849.0K | -$41.0K | -$35.0K |
| Prepaid expenses and other current and non-current assets | -$7.7M | -$3.2M | -$4.7M |
| Change in lease assets and liabilities, net | -$622.0K | -$949.0K | -$986.0K |
| Accounts payable | -$85.0K | -$17.6M | $24.8M |
| Accrued expenses | $28.8M | -$31.1M | $22.3M |
| Deferred revenue, current and non-current | -$2.8M | -$6.1M | -$15.8M |
| Other current and non-current liabilities | -$9.7M | $5.6M | -$418.0K |
| Net cash provided by (used in) operating activities - continuing operations | $37.8M | -$230.0M | -$325.4M |
| Net cash (used in) provided by operating activities - discontinued operations | $0 | -$7.5M | $45.3M |
| Net cash provided by (used) in operating activities | $37.8M | -$237.5M | -$280.0M |
| Proceeds from the sale and maturity of marketable debt securities | $323.6M | $326.3M | $334.6M |
| Purchase of marketable debt securities | -$237.1M | -$125.8M | -$443.9M |
| Purchase of intangible assets | -$58.2M | -$36.2M | -$41.6M |
| Payment of milestone | $0 | -$65.0M | $0 |
| Other | -$404.0K | -$40.0K | -$668.0K |
| Net cash provided by (used in) investing activities - continuing operations | $27.9M | $99.3M | -$151.6M |
| Net cash provided by investing activities - discontinued operations | $0 | $0 | $207.4M |
| Net cash provided by investing activities | $27.9M | $99.3M | $55.8M |
| Payment of guaranteed minimum royalty | -$2.1M | -$2.1M | -$2.1M |
| Repayment of 2025 convertible senior notes | -$68.9M | $0 | $0 |
| Proceeds from the issuance of common stock, net of issuance costs | $0 | $134.7M | $191.2M |
| Proceeds from the issuance of pre-funded warrants, net of issuance costs | $0 | $0 | $24.6M |
| Proceeds from exercise of stock options | $34.7M | $4.5M | $3.2M |
| Proceeds from the issuances under the employee stock purchase plan | $2.8M | $2.3M | $3.2M |
| Net cash (used in) provided by financing activities - continuing operations | -$33.5M | $139.4M | $220.1M |
| Net cash used in financing activities - discontinued operations | $0 | $0 | -$1.4M |
| Net cash (used in) provided by financing activities | -$33.5M | $139.4M | $218.8M |
| Effect of exchange rate changes on cash | $2.3M | -$913.0K | $2.0M |
| Net increase (decrease) in cash and cash equivalents | $34.5M | $359.0K | -$3.5M |
| Operating cash flows used for operating leases | $6.6M | $6.4M | $6.3M |
| Cash paid for interest | $8.8M | $8.8M | $8.8M |
| Accrued royalty in excess of minimum payable to the sellers of Thiola | $14.3M | $15.4M | $16.2M |
No quarter-by-quarter statement was filed.
Leadership
Who has led Travere Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
201520202025
- Chief executive officerEric M. Dube Jan 8, 2019 to now11
- Chief executive officerSteve Aselage Nov 10, 2014 to Feb 13, 201912
- PresidentSteve Aselage Jun 3, 2014 to Jun 3, 201413
- Chief financial officerLaura Clague Nov 17, 2014 to May 12, 202214
- Chief financial officerMarc L. Panoff May 24, 2013 to Feb 28, 201415
- Chief operating officerNeil F. McFarlane Aug 15, 2016 to May 16, 201916
- Chief operating officerSteve Aselage Jun 3, 2014 to Jun 3, 201413
Board members and other officers (25)
- Chief Medical OfficerJula Inrig Jan 4, 2022 to now17
- VP, Corp Controller and CAOSandra Calvin Sep 23, 2021 to now18
- Chief Commercial OfficerPeter Heerma Oct 2, 2019 to now19
- Chief Medical OfficerNoah L. Rosenberg Jul 30, 2018 to Aug 17, 202120
- SVP, GC & Corporate SecretaryElizabeth E. Reed Jan 6, 2017 to Feb 12, 202521
- Senior Vice President, R&DWilliam E. Rote Feb 15, 2017 to now22
- EVP of Research & DevelopmentAlvin Shih Jun 11, 2014 to Sep 2, 201623
- Chief Medical OfficerHoracio Plotkin Jul 12, 2013 to Dec 16, 201424
- Board memberRuth W. Brinkley Sep 16, 2021 to now25
- Board memberSuzanne Louise Bruhn Apr 9, 2020 to now26
- Board memberEric M. Dube Jan 8, 2019 to now11
- Board memberSandra Poole May 15, 2019 to now27
- Board memberJohn A. Orwin Mar 27, 2017 to now28
- Board memberRon Squarer Apr 12, 2017 to now29
- Board memberRoy D. Baynes Jul 26, 2016 to now30
- Board memberTimothy P. Coughlin Apr 2, 2015 to now31
- Board memberJohn W. Kozarich Apr 3, 2015 to May 10, 201932
- Board memberGary A. Lyons Oct 10, 2014 to now33
- Board memberJeffrey A. Meckler Oct 10, 2014 to now34
- Board memberSteven Gary Richardson Nov 8, 2013 to Dec 9, 201435
- Board memberCornelius E. Golding Dec 27, 2013 to May 19, 201636
- Board memberJeffrey Paley Dec 27, 2013 to Aug 18, 201437
- Board memberSteve Aselage Dec 27, 2013 to May 12, 202238
- General counselElizabeth E. Reed May 5, 2025 to now39
- General counselJensen Margaret E. Valeur Nov 17, 2014 to Feb 2, 201640
Former names
Timeline
Filings
549 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 69 major events, 227 insider forms, 69 large holders, 164 other. The latest 20:
- Oct 15, 2026144 EDGAR
- Sep 21, 20268-K EDGAR
- Sep 17, 2026144 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 17, 20264 EDGAR
- Sep 16, 2026144 EDGAR
- Sep 16, 2026144 EDGAR
- Sep 16, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 15, 2026144 EDGAR
The 549 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 69 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G/A
- Aug 12, 2026SCHEDULE 13G
- Aug 7, 2026SCHEDULE 13G
- Aug 6, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- Apr 30, 2026SCHEDULE 13G
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 13, 2026SCHEDULE 13G/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Jupiter Topco LLC | 11,324,191 | $643.3M | 0.3% | New |
| BlackRock, Inc. | 8,020,663 | $455.7M | 0.0% | +228,630 |
| Fmr LLC | 7,096,614 | $403.2M | 0.0% | −3,871,353 |
| Bank Of America Corp /de/ | 4,568,341 | $259.5M | 0.0% | +3,223,230 |
| State Street Corp | 4,256,224 | $241.8M | 0.0% | −703,764 |
| Vanguard Capital Management LLC | 4,108,694 | $233.4M | 0.0% | +62,882 |
| Perceptive Advisors LLC | 3,752,574 | $213.2M | 3.3% | −389,977 |
| Nomura Asset Management International Inc. | 2,812,514 | $159.8M | 0.2% | −457,999 |
| Adage Capital Partners Gp, L.l.c. | 2,569,356 | $146.0M | 0.2% | +1,592,356 |
| Geode Capital Management, LLC | 2,371,887 | $134.8M | 0.0% | +2,328 |
| Rock Springs Capital Management LP | 2,179,069 | $123.8M | 6.0% | +701,115 |
| Kynam Capital Management, LP | 2,000,000 | $113.6M | 6.3% | +430,982 |
| Stephens Investment Management Group LLC | 1,875,304 | $106.5M | 1.1% | +76,838 |
| Renaissance Technologies LLC | 1,833,079 | $104.1M | 0.1% | −133,700 |
| Emerald Advisers, LLC | 1,600,886 | $90.9M | 2.1% | +43,690 |
| Armistice Capital, LLC | 1,572,539 | $89.3M | 2.5% | −3,324,878 |
| Two Sigma Investments, LP | 1,565,656 | $88.9M | 0.1% | +57,397 |
| Vanguard Portfolio Management LLC | 1,541,617 | $87.6M | 0.0% | −167,522 |
| Goldman Sachs Group Inc | 1,535,321 | $87.2M | 0.0% | −184,400 |
| Wellington Management Group Llp | 1,533,080 | $87.1M | 0.0% | +510,808 |
| Qube Research & Technologies Ltd | 1,443,230 | $82.0M | 0.1% | +774,071 |
| D. E. Shaw & Co., Inc. | 1,440,469 | $81.8M | 0.1% | +603,925 |
| Driehaus Capital Management LLC | 1,439,134 | $81.8M | 0.5% | +156,616 |
| Marshall Wace, Llp | 1,333,207 | $75.7M | 0.1% | +1,154,671 |
| Bnp Paribas Financial Markets | 1,156,960 | $65.7M | 0.0% | +1,047,578 |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARSteve Aselage, President
- 14
- 15
- 16
- 17SEC EDGARJula Inrig, Chief Medical Officer
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25SEC EDGARRuth W. Brinkley, Board member
- 26SEC EDGARSuzanne Louise Bruhn, Board member
- 27SEC EDGARSandra Poole, Board member
- 28SEC EDGARJohn A. Orwin, Board member
- 29SEC EDGARRon Squarer, Board member
- 30SEC EDGARRoy D. Baynes, Board member
- 31SEC EDGARTimothy P. Coughlin, Board member
- 32SEC EDGARJohn W. Kozarich, Board member
- 33SEC EDGARGary A. Lyons, Board member
- 34SEC EDGARJeffrey A. Meckler, Board member
- 35SEC EDGARSteven Gary Richardson, Board member
- 36SEC EDGARCornelius E. Golding, Board member
- 37SEC EDGARJeffrey Paley, Board member
- 38SEC EDGARSteve Aselage, Board member
- 39SEC EDGARElizabeth E. Reed, General counsel
- 40